At $AFX (+1,13%) looks like it is bottoming out. What are your thoughts? I am down approx. 25% and am considering buying another tranche.

My development in this area has been very mixed. After I sold in December $WBA (+3,6%) after a risky purchase - to lower the buy in - with +/- 0, my investment in $AFX (+1,13%) was abruptly terminated, leaving me with a hefty loss, and shortly afterwards I unfortunately also lost my shares in $UNH (+0,76%) but still with a profit of 8%. Today I decided to recoup my losses and sold my $BMY (+1,35%) sold. It was a nice trade, plus the €245 dividend plus the payment on February 3rd. The uncertainty in the sector has become too great for me and I want to watch from the sidelines what the new US government will do. Marty Makary as the planned head of the FDA will certainly not strike as brutally as some fear, but there could be changes and difficulties in the area of approval procedures. This would also affect Bristol, which should and must bring a few good products from its pipeline onto the market in the next few years. The acquisition of Karuma together with the approval of KarXT has provided a brief boost, but is not enough to compensate for the expiry of patent protection for Revlimid, Opdivo and especially Eliquis in the next few years. They account for over USD 12 billion of sales and patent protection expires in the EU in 2026 and in the US in 2028. This does not mean that Eliquis will no longer be sold, but a not insignificant proportion is likely to be lost to generics. In addition, CMS has already negotiated price reductions of 56% for 2026. Coupled with the political uncertainties, I have taken the money with me for the time being and will wait and see. I still have to deal with $NOVO B (-2%) ...., which is currently the biggest loss-maker in my portfolio with a drop of almost 17%.

Please let me know your assessment of the market in this sector.

Happy New Year everyone! We are starting the new year with adjustments to the Sina ETF. (The performance here below somehow no longer corresponds to the actual performance, but so be it...) After this post you'll have peace and quiet from my ETF again :D

I sold some stocks and invested the dividends I received last year. That left me with 19 euros in cash, so it's still a 40-share ETF ;)

If this were my only portfolio, I would probably have held more cash and not reinvested directly, as the entry point doesn't always seem optimal. But I also proceeded without regard to entry points.

For the question of how high the profits or losses were, please refer to the portfolio.

Out are:

$STLAM (+1,13%) (loss)

$AFX (+1,13%) (loss)

$MC (+1,15%) (loss)

$OR (-0,56%) (loss)

$7203 (+2,04%) (loss)

$D05 (+3,26%) (Profit)

$RHM (+1,79%) (Profit)

$ENR (-0,86%) (Profit; also dropped from my "real" portfolio)

Partial sale:

$WMT (-0,43%) at 50%

Increased by:

$AAPL (-0,39%)

$MSFT (-0,73%)

$ASML (-0,64%) Since the position was down over 20%, but I am convinced in the long term

$GOOGL (-0,76%)

New additions:

$BKNG (-1,83%)

$JPM (+1,47%)

$NU (+0,46%)

$COST (+0,37%)

$AFL (+0,47%)

$INTC (+0,91%)

$CRM (-1,06%)

$NOVO B (-2%)

How should I start? My portfolio has increased by almost 3.75 times, even though I've been struggling with a few problems since June and can hardly save any more.

My BAföG has not yet been approved, which is why I have to be financially cautious and hope that I can make ends meet with my remaining funds.

The year has been exciting - I can't guarantee you whether the figures here are accurate, and to be honest I don't think they are, because so far they've almost always been wrong. Nevertheless, it gives you a good insight into my portfolio.

And my goals for 2025? Honestly, I have no idea! I'll have to see how my studies and my life as a whole are going before I can set any concrete goals, but I'll have some fun: Here are my top and flop 5 that I still hold.

$SOFI (-2,18%)
$BTC (-1,04%)
$FWONA
$D05 (+3,26%)
$FTNT (-1,67%)

$AIXA (+3,84%)
$EVT (+2,23%)
$AFX (+1,13%)
$MRNA (+11,84%)
$CELH

I wish you all a happy new year!

year!

Analyst updates, 17.12.

⬆️⬆️⬆️

• - UBS raises the price target for AMAZON from USD 230 to USD 264. Buy. $AMZN (-1,81%)
• - CITIGROUP raises the target price for ALLIANZ SE from EUR 286 to EUR 314.40. Neutral. $ALV (+0,87%)
• - BARCLAYS raises the target price for DHL GROUP from EUR 37.50 to EUR 38. Equal-Weight. $DHL (+0,81%)
• - DEUTSCHE BANK RESEARCH upgrades AIRBUS from Hold to Buy and raises target price from EUR 155 to EUR 185. $AIR (-0,69%)
• - BERENBERG raises the price target for MUNICH RE from EUR 525 to EUR 552. Hold. $MUV2 (+1,8%)
• - KEPLER CHEUVREUX raises the price target for ADESSO from EUR 80 to EUR 100. Hold. $ADN1 (-1,88%)
• - WARBURG RESEARCH raises the price target for FMC from EUR 31 to EUR 36. Sell. $FME (-0,55%)
• - DEUTSCHE BANK RESEARCH raises the target price for AUTO1 from EUR 12 to EUR 20. Buy. $AG1 (+6,19%)
• - DEUTSCHE BANK RESEARCH raises the price target for MTU from EUR 329 to EUR 337. Hold. $MTX (+0,65%)
• - DEUTSCHE BANK RESEARCH raises the price target for HENSOLDT from EUR 37 to EUR 41. Buy. $HAG (+2,99%)
• - DEUTSCHE BANK RESEARCH raises the target price for ROLLS-ROYCE from GBP 5.55 to GBP 6.30. Buy. $RR. (+1,76%)
• - BOFA raises the target price for INFINEON from EUR 36 to EUR 40. Buy. $IFX (+2,21%)
• - BOFA raises the price target for STMICRO from EUR 29 to EUR 30. Buy. $STMPA (+1,36%)
• - BOFA raises the target price for NOKIA from EUR 4.07 to EUR 4.58. Neutral. $NOKIA (+3,21%)

⬇️⬇️⬇️

• - JPMORGAN downgrades TRANSMEDICS from Overweight to Neutral and lowers target price from 116 USD to 75 USD. $TMDX (+4,17%)
• - BOFA lowers the price target for SILTRONIC from EUR 59 to EUR 46. Underperform. $WAF (-1,5%)
• - HSBC lowers the price target for CARL ZEISS MEDITEC from EUR 66 to EUR 54. Hold. $AFX (+1,13%)
• - KEPLER CHEUVREUX lowers the price target for HEIDELBERGER DRUCK from EUR 1.25 to EUR 1. Hold. $HBGRY
• - KEPLER CHEUVREUX lowers the price target for EVONIK from EUR 25 to EUR 21. Buy. $EVK (-0,73%)
• - KEPLER CHEUVREUX lowers the price target for NORDEX from EUR 17 to EUR 14. Buy. $NDX1 (-0,29%)

$AFX (+1,13%) how low can it go 🙆🏻‍♂️

Turnaround candidate 2025, what is your opinion?

Analyst updates, 16.12.

⬆️⬆️⬆️

• JEFFERIES raises the price target for AMAZON from USD 235 to USD 275. Buy. $AMZN (-1,81%)
• CITIGROUP raises the price target for MUNICH RE from EUR 475 to EUR 522. Neutral. $MUV2 (+1,8%)
• BERENBERG raises the price target for RHEINMETALL from EUR 655 to EUR 750. Buy. $RHM (+1,79%)
• WARBURG RESEARCH raises the price target for PORSCHE SE from EUR 36 to EUR 37. Hold. $PAH3 (-0,34%)
• WARBURG RESEARCH raises the price target for HENSOLDT from EUR 40 to EUR 42. Buy. $HAG (+2,99%)
• JEFFERIES raises the target price for SHELL from GBP 31 to GBP 32. Buy. $SHEL (+2,21%)

⬇️⬇️⬇️

• BERNSTEIN lowers the price target for PORSCHE SE from EUR 46 to EUR 42. Market Perform. $PAH3 (-0,34%)
• HSBC downgrades SAP to Hold. Target price EUR 260. $SAP (+1,79%)
• LOOP CAPITAL downgrades NETFLIX to Hold. Target price 950 USD. $NFLX (+0,31%)
• EXANE BNP lowers the price target for MERCEDES-BENZ from EUR 57 to EUR 54. Underperform. $MBG (+0,16%)
• JEFFERIES downgrades FORD from Hold to Underperform and lowers target price from USD 12 to USD 9. $F (-0,62%)
• CITIGROUP lowers the price target for THYSSENKRUPP from EUR 5.80 to EUR 5.50. Buy. $TKA (-2,19%)
• STIFEL lowers the price target for AIXTRON from EUR 20 to EUR 18. Hold. $AIXA (+3,84%)
• PARETO downgrades TRATON to Hold. Target price EUR 32.50. $8TRA (-1,35%)
• DEUTSCHE BANK RESEARCH lowers the target price for KINGFISHER from GBP 3.50 to GBP 3.40. Buy. $KGF (-1,25%)
• METZLER lowers the price target for CARL ZEISS MEDITEC from EUR 104 to EUR 90. Buy. $AFX (+1,13%)
• BERENBERG lowers the price target for SCHOTT PHARMA from EUR 32 to EUR 28. Hold. $1SXP (+2,36%)
• CITIGROUP downgrades 1&1 to Neutral. Target price EUR 15. $1U1 (+0,92%)

$AFX (+1,13%) received by e-mail this morning.

Carl Zeiss Meditec AG / Key word(s): Annual Report/Annual Results

Carl Zeiss Meditec closes fiscal year 2023/24 with slightly lower revenue - forecast for adjusted EBIT achieved

11.12.2024 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec closes fiscal year 2023/24 with slightly lower revenue - forecast for adjusted EBIT achieved

Restrictive investment climate and weak consumer sentiment weigh on revenue and earnings development

JENA, December 11, 2024

Carl Zeiss Meditec achieved revenue of around EUR 2,066.1 million in fiscal year 2023/24 (previous year: EUR 2,089.3 million). This corresponds to a decline in revenue of -1.1% (adjusted for currency and acquisition effects: -4.8%). Adjusted earnings before interest and taxes (EBIT) fell to around EUR 245.9 million (previous year: EUR 362.9 million) and was therefore around the mid-point of the guidance after 9M 2023/24 of EUR 225 - 275 million. The adjusted EBIT margin, based on sales excluding the contribution from the DORC acquisition, amounted to 12.5% (previous year: 17.4%).

In the 2023/24 financial year, the Strategic Business Unit (SBU) Ophthalmology recorded slight growth of +0.8% (adjusted for currency effects: +1.8%, adjusted for currency and acquisition effects: -4.5%) with sales of 1,589.2 million euros (previous year: 1,576.5 million euros). The first-time contribution from the acquisition of DORC[1], a company specializing in retinal surgery, amounted to 99.9 million euros.

In the reporting period, weaker sales of consumables, particularly in connection with the reduction in inventories of surgical consumables in the Chinese sales channel, which was successfully completed in the first half of the year, and the volume-based procurement of intraocular lenses in China, as well as declining demand in the device business, due among other things to high interest rates and increased financing costs as well as health policy uncertainties in some core markets such as North America, Germany and Japan, led to a fall in sales. The consolidation of DORC in the second half of the year had a supporting effect.

The Microsurgery strategic business unit achieved sales of 477.0 million euros (previous year: 512.8 million euros), which corresponds to a decline of -7.0% (adjusted for currency effects: -5.6%). This was primarily due to weak neurosurgery business, which was also affected by a reluctance to invest in various markets, particularly in North America due to high financing costs.

EMEA with double-digit percentage sales growth

In the EMEA region[2], sales increased by +12.9% (adjusted for currency effects: +14.3%) to EUR 584.3 million (previous year: EUR 517.3 million) in the reporting period. Positive contributions to growth came from France, Italy and Spain, among others.

Sales in the Americas region fell significantly by -6.6% (adjusted for currency effects: -5.4%) from 570.7 million euros to 532.9 million euros. Sales in both the USA and Latin America declined.

The APAC region[3] also recorded a decline in sales. Sales amounted to 949.0 million euros (previous year: 1,001.2 million euros) and therefore fell by -5.2% (adjusted for currency effects: -4.3%). Growth contributions came in particular from the markets of South East Asia and Australia. China declined due to a subdued peak season for refractive laser surgery in the summer months of 2024 compared to the previous year and the normalization of refractive consumables inventories.

EBIT and EBIT margin significantly below previous year

In fiscal year 2023/24, Carl Zeiss Meditec generated operating earnings (earnings before interest and taxes: EBIT) of EUR 194.5 million (previous year: EUR 348.1 million). The decline is mainly due to the weak revenue development and a significantly less favorable product mix compared to the previous year, mainly as a result of the reduction in inventories of surgical consumables in the Chinese sales channel and the weaker than expected demand for refractive treatments in China in the seasonally important summer months. Adjusted for the effects associated with the DORC acquisition, operating costs were reduced slightly by around 1% for the year as a whole - this was due in particular to more stringent resilience measures in the areas of research and development as well as sales and marketing over the course of the financial year.

The EBIT margin was 9.4% in the 2023/24 financial year (previous year: 16.7%). This includes scheduled negative special effects in connection with the acquisition of DORC. In Q4 2023/24, amortization from purchase price allocation was incurred for the first time. Other significant burdens resulted from the inventory revaluation in connection with the initial consolidation of DORC and integration costs. Furthermore, intangible assets from a previous acquisition (CZM Cataract Technologies Inc., Reno, formerly "IanTECH, Inc.") were impaired in the fourth quarter of 2023/24 due to new, more conservative planning assumptions. This was offset by proceeds already recognized in Q2 2023/24 from a settlement payment to settle a legal dispute with competitor Topcon Ltd. in the USA.

Adjusted for one-off effects and the pro rata earnings contribution from the DORC acquisition, the EBIT margin amounted to 12.5% (previous year: 17.4%). EBITA, which only includes amortization from purchase price allocation (including the impairment of the assets of CZM Cataract Technologies Inc.), amounted to EUR 248.9 million (previous year: EUR 358.6 million), while the EBITA margin was 12.0% (previous year: 17.2%). Earnings per share also declined to EUR 2.01 (previous year: EUR 3.25). Taking into account the lower profit and the net financial debt of EUR -327.4 million (previous year: net liquidity of EUR 863.8 million) that arose for the first time as a result of the DORC acquisition, a dividend of EUR 0.60 (previous year: EUR 1.10) will be proposed.

Forecast for the new financial year 2024/25

The company expects the global macroeconomic environment to remain challenging in financial year 2024/25 and does not anticipate a rapid recovery in the investment climate for devices or continued pressure on consumer spending on elective procedures - although the underlying long-term positive development trends for the market described above remain fundamentally intact. Moderate sales growth is expected for the 2024/25 financial year, including the additional contribution from the full-year consolidation of DORC.

In the 2024/25 financial year, EBITA and the EBITA margin are expected to be stable to slightly higher (FY 2023/24: EBITA EUR 248.9 million, EBITA margin: 12.0%).

To ensure that targets are achieved, the cost containment measures ("Resilience" program) will remain in place in order to keep the cost trend before consolidation of DORC roughly stable.

New product launches such as KINEVO® 900 S and possible further VISUMAX® 800 approvals offer additional potential for business development over the course of the year, despite some remaining uncertainties regarding the timing of approvals. There are also additional opportunities in targeted public measures to promote the economy and healthcare investments, particularly in the Chinese market.

The aim is to gradually increase the EBITA margin in subsequent years. In the long term, the company expects to achieve an EBITA margin of around 16-20% again (2023/24: 12.0%). This is to be supported by the increasing share of recurring revenue, for example from consumables, implants and services. Recurring revenue amounted to 47% in the 2023/24 financial year (previous year: 43%), with the DORC acquisition making a particularly positive contribution.

Dr. Markus Weber, CEO of Carl Zeiss Meditec AG, comments on the results of the fiscal year: "2023/24 was a difficult fiscal year for us - we had to cope with a significant slowdown in the global economy and the consumer climate as well as a pronounced reluctance to invest in the device business in several core markets - especially in North America. The resilience measures that were tightened up over the course of the financial year have had the expected effect and the forecast for adjusted EBIT, which was lowered in June, has therefore been safely achieved. The general conditions for 2024/25 are not expected to become any easier - the weakness currently being observed in the Chinese market in particular prompts us to adopt a cautious outlook. Nevertheless, we are confident that we will be able to return to growth and achieve at least stable to slightly positive EBITA development in the coming financial year. In subsequent years, we will also gradually return to higher profitability, supported by the growth of our recurring sales."

Turnover by strategic business division

Figures in million euros 12 months

2023/24 12 months

2022/23 Change on previous year % Change

on previous year % (currency-adjusted)

Ophthalmology 1,589.2 1,576.5 +0.8 +1.8

Microsurgery 477.0 512.8 -7.0 -5.6

Group as a whole 2,066.1 2,089.3 -1.1 0.0

Turnover by region

Figures in million euros 12 months

2023/24 12 months

2022/23 Change on previous year % Change

on previous year % (currency-adjusted)

EMEA 584.3 517.3 +12.9 +14.3

Americas 532.9 570.7 -6.6 -5.4

APAC 949.0 1,001.2 -5.2 -4.3

Group as a whole 2,066.1 2,089.3 -1.1 0.0

Further information on our publication and the analyst conference call on the results for the 2023/24 financial year can be found at

https://www.zeiss.de/meditec-ag/investor-relations/finanzkalender/telefonkonferenzen.html

Contact for investors and press

Sebastian Frericks

Head of Group Finance & Investor Relations, Carl Zeiss Meditec AG

Tel. 03641 220-116

E-mail: investors.med@zeiss.com

www.zeiss.de/presse

⬆️⬆️⬆️

- KEPLER CHEUVREUX raises the price target for SAP from EUR 200 to EUR 230. Hold. $SAP (+1,79%)

- UBS upgrades HUGO BOSS from Neutral to Buy and raises target price from EUR 41 to EUR 49. $BOSS (+2,28%)

- BOFA raises the price target for FRAPORT from EUR 55 to EUR 56. Neutral. $FRA (+0,87%)

- UBS raises target price for RICHEMONT from CHF 144 to CHF 150. Buy. $CFR (+1,48%)

- BOFA upgrades HOCHTIEF from Neutral to Buy and raises target price from EUR 112 to EUR 140. $HOT (-1,52%)

- JPMORGAN raises target price for FEDEX from USD 350 to USD 366. Overweight. $FDX (+1,2%)

- JPMORGAN raises the price target for ROCHE from CHF 220 to CHF 230. Underweight. $ROG (+2,74%)

- UBS upgrades BMW from Neutral to Buy and raises target price from EUR 75 to EUR 83. $BMW (-0,81%)

- JEFFERIES raises target price for UNICREDIT from EUR 47 to EUR 49. Buy. $UCG (+0,06%)

⬇️⬇️⬇️

- HAUCK AUFHÄUSER IB lowers the price target for DELIVERY HERO from EUR 61 to EUR 52. Buy. $DHER (+6,28%)

- BARCLAYS lowers the target price for VOLKSWAGEN VORZÜGE from EUR 110 to EUR 100. Overweight. $VOW (+0,33%)

- BARCLAYS lowers the target price for PORSCHE SE from EUR 35 to EUR 30. Underweight. $PAH3 (-0,34%)

- UBS downgrades MERCEDES-BENZ from Buy to Neutral and lowers target price from EUR 72 to EUR 55. $MBG (+0,16%)

- EXANE BNP downgrades HYPOPORT from Outperform to Neutral. $HYQ (-3,38%)

- HAUCK AUFHÄUSER IB lowers the price target for IBU-TEC from EUR 12 to EUR 7.40. Hold. $IBU (+0%)

- KEPLER CHEUVREUX downgrades SYMRISE from Buy to Hold and lowers target price from EUR 122 to EUR 114. $SY1 (-0,3%)

- DEUTSCHE BANK RESEARCH lowers the price target for SANOFI from EUR 90 to EUR 85. Sell. $SAN (+2,5%)

- JPMORGAN lowers the price target for CARL ZEISS MEDITEC from EUR 56 to EUR 45. Underweight. $AFX (+1,13%)

- JPMORGAN lowers the price target for SARTORIUS from EUR 290 to EUR 275. Overweight. $SRT (+6%)

22.11.2024

Snowflake rises up to 25% + Bitcoin almost at $100,000 + Rotation in MDax + Carl Zeiss Meditec falls to low since 2018 + Berenberg rates CTS Eventim a 'Buy' - target 100 euros

The Snowflake $SNOW (-2,05%) shares rose 25% after the data analytics provider raised its full-year product revenue guidance and announced that it has partnered with AI company Anthropic to expand its cloud services.

The Bitcoin $BTC (-1,04%) reached just under $100,000 overnight and currently stands at $99,000.

What do you think, will Bitcoin reach $100,000 in November, or even today?

The US bank JPMorgan expects only a few changes for the next index review by Deutsche Börse at the beginning of December. While everything should remain the same in the leading Dax index, analyst Pankaj Gupta expects a swap in the mid-cap index below it, the MDax, where, according to him, industrial recycler Befesa will probably make way for drug researcher Evotec $EVT (+2,35%) will have to give way. Befesa $BFSA (-5,71%) would be relegated to the SDax, the index of smaller stocks. In the TecDax, Gupta expects that SMA Solar $S92 (+1,46%) will make way for the internet service provider Ionos $IOS (-0,57%) Deutsche Börse will review the indices of the Dax family (Dax, MDax, SDax and TecDax) on Wednesday, December 4, and announce any changes after the close of trading in the US. The changes will come into effect on Monday, December 23.

The downturn in the share price of Carl Zeiss Meditec $AFX (+1,13%) continued on Thursday with a new six-year low. The trend at the medical technology manufacturer has been pointing downwards since 2021, and this trend has intensified in the current year since March. At that time, the shares were still trading above 123 euros. On Thursday, the drop of over four percent pushed them down to 54.45 euros. This marks the lowest level since April 2018. With brief exceptions in August and late October and early September, the shares have been trading below the 200-day line, which is a popular long-term indicator for chart-oriented investors, for months. Jack Reynolds-Clark from RBC Research did not paint a good picture for the company at the beginning of November, downgrading it to "Sector Perform" due to uncertain demand in the various end markets. He emphasized that the consensus for 2025 depicts a rather optimistic scenario that is difficult to justify.

The private bank Berenberg has raised its rating for CTS Eventim $EVD (+0,74%) to "Buy" with a target price of 100 euros. The event organizer presented mixed quarterly figures, wrote analyst Gerhard Orgonas on Thursday evening. He cut his earnings estimates until 2026, taking into account integration costs and a slightly lower ticketing margin.

• CTS Eventim increased its consolidated revenue by 15.8 percent to EUR 2.027 billion in the first nine months of 2024. Adjusted EBITDA grows by 12.1 percent to EUR 322.7 million in the same period. The company's management is sticking to its forecast and expects a significantly higher Adjusted EBITDA for the full year compared to the previous year.
• CTS Eventim records a 22.9 percent increase in revenue to EUR 564.6 million in the Ticketing segment and a 13.6 percent increase to EUR 1.494 billion in the Live Entertainment segment. The company is also awarded the contract for the construction and operation of a new large arena by Wien Holding.

Friday: Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Schloss Wachenheim EUR 0.60

Cummins Inc. USD 1.82

CRH 0.35 GBP

Quarterly figures / company dates Europe

No time specified: Vinci Investor Day | Unilever Capital Markets Day

Economic data

• 08:00 DE: GDP (2nd release) 3Q calendar and seasonally adjusted yoy FORECAST: +0.2% yoy 1st release: +0.2% yoy 2nd quarter: -0.3% yoy calendar-adjusted yoy FORECAST: -0.2% yoy 1st release: -0.2% yoy 2nd quarter: -0.3% yoy
• 09:15 FR: Purchasing Managers' Index/PMI non-manufacturing (1st release) November FORECAST: 49.0 PREV: 49.2 Total Purchasing Managers' Index (1st release) FORECAST: 48.1 PREV: 48.1
• 09:15 FR: Purchasing Managers' Index/PMI manufacturing (1st release) November FORECAST: 44.0 PREVIOUS: 44.5
• 09:30 DE: Purchasing Managers' Index/PMI non-manufacturing (1st release) November PROGNOSE: 51.8 PREVIOUS: 51.6 Total Purchasing Managers' Index (1st release) PROGNOSE: 48.3 PREVIOUS: 48.6
• 09:30 DE: Purchasing Managers' Index/PMI manufacturing (1st release) November FORECAST: 43.0 PREVIOUS: 43.0
• 10:00 EU: Purchasing Managers' Index/PMI non-manufacturing Eurozone (1st release) November FORECAST: 51.5 previously: 51.6
• 10:00 EU: Purchasing Managers' Index/PMI manufacturing Eurozone (1st release) November PROGNOSE: 46.0 PREVIOUS: 46.0 Total Purchasing Managers' Index (1st release) PROGNOSE: 49.8 PREVIOUS: 50.0
• 10:30 UK: Purchasing Managers' Index/PMI non-manufacturing (1st release) November FORECAST: 52.0 PREVIOUS: 52.0
• 10:30 UK: Purchasing Managers' Index/PMI Manufacturing (1st release) November FORECAST: 50.0 PREVIOUS: 49.9
• 15:45 US: Purchasing Managers' Index/PMI Services (1st release) November FORECAST: 55.0 PREVIOUS: 55.0
• 15:45 US: Purchasing Managers' Index/PMI Manufacturing (1st release) November FORECAST: 48.8 PREVIOUS: 48.5
• 16:00 US: Consumer Sentiment Index Uni Michigan (2nd survey) November FORECAST: 73.5 1st survey: 73.0 previous: 70.5